Pharmacotherapy of obesity: what’s new?

Cover Page

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access


The lifestyle change that underlies the treatment of such a prevalent chronic disease as obesity is often insufficient to successfully clinically relevant reduce body weight, especially in the presence of comorbid conditions and diseases (type 2 diabetes, atherogenic dyslipidemia, arterial hypertension, ischemic heart disease, hyperuricemia and gout, obstructive sleep apnea syndrome, polycystic ovary syndrome and other menstrual irregularities etc.). The availability in our country until recently, only two drugs for the treatment of obesity is extremely limited choice in the case of existing contraindications to this or another drug or the appearance of any side effects. The registration in Russia in 2016 of a new drug for the treatment of obese patients, including morbid or complicated concomitant diseases and conditions, an analogue of human glucagon-like peptide-1 — liraglutide in a dose of 3.0 mg, has replenished the arsenal of obesity pharmacotherapy and substantially extended capabilities of management of obesity and overweight including patients with severe comorbidities.

Full Text

Restricted Access

About the authors

Ekaterina A. Troshina

Endocrinology Research Centre

ORCID iD: 0000-0002-8520-8702
SPIN-code: 8821-8990

MD, PhD, Professor

Russian Federation, 11, Dm. Ulyanova street, Moscow, 117036

Ekaterina V. Ershova

Endocrinology Research Centre

Author for correspondence.
ORCID iD: 0000-0002-6220-4397
SPIN-code: 6728-3764


Russian Federation, 11, Dm. Ulyanova street, Moscow, 117036


  1. [Internet]. World Health Organization: Obesity and Overweight. WHO fact sheet №311 [updated Oct 2017; cited 8 Sep 2017]. Available from:
  2. Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32(9):1431-1437.doi: 10.1038/ijo.2008.102
  3. Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science. 2003;299(5608):853-855.doi: 10.1126/science.1079857
  4. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350.doi: 10.1056/NEJM200105033441801
  5. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2003;27(1):155-161. doi: 10.2337/diacare.27.1.155
  6. Curfman GD, Morrissey S, Drazen JM. Sibutramine — another flawed diet pill. N Engl J Med. 2010;363(10):972-974.doi: 10.1056/NEJMe1007993
  7. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults. Arch Intern Med. 2000;160(9):1321.doi: 10.1001/archinte.160.9.1321
  8. Holecki M, Zahorska-Markiewicz B, Nieszporek T, et al. Impact of the mass-reductive therapy with orlistat on 25-(OH)-D3 and PTH concentration in sera of obese, menopausal women. Endokrynol Pol. 2005;56(3):240-245.
  9. Чигарькова О.В. Состояние костной ткани у женщин с ожирением в постменопаузе. Влияние снижения массы тела на минеральную плотность кости и показатели костного метаболизма: Дис. … канд. мед. наук. М. 2008. [Chigar’kova OV. Sostoyaniye kostnoy tkani u zhenshchin s ozhireniyem v postmenopauze. Vliyaniye snizheniya massy tela na mineral’nuyu plotnost’ kosti i pokazateli kostnogo metabolizma. [dissertation]. M. 2008. (In Russ.)].
  10. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000;356(9248):2119-2125. doi: 10.1016/S0140-6736(00)03491-7
  11. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-917. doi: 10.1056/NEJMoa1003114
  12. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22.
  13. le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-1409.doi: 10.1016/s0140-6736(17)30069-7
  14. Wharton S, Jacobsen P, Arrone L. Early responders to liraglutide 3.0 mg as adjunct to diet and excercise from the SCALE Maintenance trial. Proceedings of the 24th European Congress on Obesity; 2017 May 17—20; Porto.
  15. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-699.doi: 10.1001/jama.2015.9676
  16. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-1319. doi: 10.1038/ijo.2016.52
  17. Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8(6):402-424.doi: 10.1159/000442721

Copyright (c) 2021 Troshina E.A., Ershova E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies